Follow us on:

Linkedin Facebook

Nuformix hosting online Q&A session on 13 June 2023

Nuformix plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30 p.m. GMT on Tuesday 13 June 2023.  This session is open to all existing and prospective shareholders.  Those who wish to attend should register via the following link where they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_fV_2UztcQLSl1S1tC4vTGg

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: [email protected]

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

Latest Company News

Nuformix plc

Nuformix Executive Director discusses patent updates, interim results and future plans (LON:NFX)

Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding reveals insights on new patents for NXP002 & NXP004, interim results, and future plans in an exclusive interview.

Nuformix Secures Key Patents and Outlines Future Plans for NXP002 and NXP004 (VIDEO)

Nuformix Plc provides a patent update for its NXP002 and NXP004 programs in fibrosis and oncology. Learn more in this interview with Executive Director Dr. Dan Gooding.
Nuformix plc

Nuformix continues to advance and exploit current assets within the portfolio

Nuformix plc (LON:NFX) announces unaudited results for the six months ended 31 March 2024, highlighting progress in drug repurposing for fibrosis and oncology.
Nuformix plc

Nuformix updates on patents grants for NXP002 & NXP004

Nuformix plc (LON:NFX) announces patent updates for NXP002 and NXP004, highlighting advancements in IPF treatment and cocrystal development.
Nuformix plc

Nuformix to raise £150,000 for NXP002 programme

Nuformix plc (LON:NFX) to raise £150,000 through a subscription for 75,000,000 new ordinary shares to fund the NXP002 programme for idiopathic pulmonary fibrosis.
Nuformix plc

Nuformix plc Innovative Drug Repurposing with Breakthroughs in Fibrosis and Oncology

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.